Objective: The clinical course and underlying molecular causes in patients with glioblastoma presenting with seizures are poorly understood. Here we investigated clinical features and carrier systems as well as a transaminase relevant in glutamate homeostasis in patients with glioblastoma.
IDH-1 wild-type tumors express the branched-chain amino acid transaminase 1 (BCAT1), which among other things is relevant for glutamate synthesis in glioblastoma. 4 Glutamate is known for its epileptogenic potential in high-grade gliomas, 5 since experimental in vitro and in vivo studies have shown a relationship between glutamine/glutamate carrier systems and TAS in glioblastoma. 6 Three glutamate channels (SLC1A2, SLC38A3, and SLC7A11), in particular, are relevant in this context. SLC1A2 (EAAT2) is the major channel for glutamate reuptake in the brain; SLC38A3 is a glutamine transporter found exclusively in astrocytes and stimulated by glutamate; and SLC7A11, is also a glutamate transporter, thereby contributing to glioma aggressiveness. 6, 7 Whereas glutamate carrier systems and BCAT1 seem to be related to higher aggressiveness of tumors and shorter survival of patients, contradicting clinical data suggest that seizures as a presenting symptom in glioblastoma are correlated with longer survival. 8 BCAT1, yet unknown for its relation to seizures, is critical for glioma cell proliferation. This is due to its role as a key player in glutamate synthesis, which is correlated with survival and proliferation of glioblastoma cells. 9 Here we investigate clinical features, glutamate channel expression patterns of SLC1A2, SLC38A3, and SLC7A11, as well as the expression of BCAT1, and their impact on seizures in patients with glioblastoma as well as their survival.
| METHODS
We retrospectively identified all patients with histologically proven primary glioblastoma from our glioma database, selecting a homogenous treatment period between January 2013 and December 2014. Patients were divided into 2 groups: those with seizures as a presenting symptom and those without. Seizures were defined as focal and bilateral convulsive seizures, or both. The following clinical characteristics were included: sex, age, type of seizure, tumor location, adjuvant therapy, and overall survival. Tumor volume (T1 contrast-enhancing lesions) and edema (fluid-attenuated inversion recovery [FLAIR] sequences) were measured using MRIcron (Version 17, NITRC, TCG, open-source online platform for MRI editing).
Samples were taken immediately after surgery and analyzed by the institute of neuropathology. Samples were frozen for downstream analysis and handled accordingly. Quantitative polymerase chain reaction (qPCR) was done as described previously. 10 Total RNA was extracted using TRIzol (Invitrogen, Thermo Fisher Scientific) and treated with RNase-free DNase (Qiagen). Messenger RNA (mRNA) expression analysis was carried out using TaqMan Universal PCR Master Mix (Thermo Fisher Scientific). RNA concentration was quantified using NanoDrop RNA 6000 nano-assays and analyzed using the STEP one PLUS Applied Biosystems PCR machine (Thermo Fisher Scientific). The following primer pairs were purchased from Thermo Fisher: SLC1A2 (HS01102423_m1), SLC38A3 (HS01006103_m1), SLC7A11 (HS00921938_m1), and BCAT1 (HS003998962_m1). Data are expressed as mean ± standard deviation (SD). The unpaired 2-tailed Student's t test was used for comparison between the 2 groups. All figures and statistical analysis were designed and carried out using GraphPad Prism version 7.01 (GraphPad Software) and SPSS (IBM SPSS, Statistics for Windows, version 23.0).
| RESULTS
We identified 107 patients diagnosed with glioblastoma, IDH-1 wild-type, from the beginning of 2013 to the end of 2014. IDH-1 mutated tumors (n = 4) were excluded to eliminate secondary glioblastomas from further analysis. Twenty-three patients initially presented with seizures (22.3%). Mean age for the seizure group was 62.3 years and 65 years for the nonseizure group. The seizure group consisted of 14 male and 9 female patients, whereas in the nonseizure group, there were 43 male and 41 female patients. In the seizure group, 9 tumors were temporal, 4 frontal, 4 parietal, 3 in the splenium, 2 insular, and one occipital. In the nonseizure group, we found 21 temporal, 27 frontal, 6 parietal, 8 in the splenium, 8 insular, 10 occipital, one cerebellar and 3 mesencephalic gliomas. There was no difference found in the proliferation marker Ki-67 between the 2 groups ( Table 1) .
The T1 contrast-enhancing tumor volume was significantly smaller in the seizure than in the nonseizure group (24.81 ± 4.32 vs 44.43 ± 3.29 cm³; P value: 0.004; Figure 1) . Furthermore, tumor edema as measured in FLAIR sequences was significantly less in the seizure than in the nonseizure group (64.6 ± 10.64 vs 95.62 ± 6.68 cm³; P value : 0.028; Figure 1 ).
Key Points
• Seizures in glioblastoma arise from small tumors with little edema • Glioblastoma presenting with seizures show up-regulation of glutamate carrier systems • Oversupply of glutamate might be due to overexpression of branched-chain amino acid transaminase 1 (BCAT-1)
Expression of glutamine/glutamate carrier systems showed no significant differences for SLC1A2 (between the 2 groups), whereas expression of SLC38A3 and SLC7A11 was significantly up-regulated in the seizure group (4.005 ± 1.00 vs 17.77 ± 5.11; P = 0.0007 and 1.726 ± 0.58 vs 4.173 ± 0.94; P = 0.0021, respectively; Figure 2 ). BCAT1 was significantly elevated in glioblastoma patients with seizures (0.9406 ± 0.18 vs 5.097 ± 1.51; P = 0.0013; Figure 3 ) compared to those without seizures. Eighty-seven patients received concomitant radio-chemotherapy with temozolomide, 9 received radiotherapy only, 6 received chemotherapy with temozolomide only, and 5 received no adjuvant therapy. Overall survival showed no significant differences between the 2 groups (Figure 4) . Cox regression analysis found gross total resection to be an independent factor for better survival but not O6-methylguanine-DNA methyltransferase (MGMT) methylation status, localization, and age (Table 2 ).
| DISCUSSION
In our series, patients with seizures as presenting symptoms of an IDH-1 wild-type glioblastoma have smaller tumors with less edema at the time of initial presentation than patients without seizures. Two of 3 investigated glutamate transporters, namely SLC38A3 and SLC7A11, were significantly up-regulated in the seizure group, as was BCAT1, which is involved in glutamate synthesis. The patients experiencing seizures as first symptom had a similar survival compared to the control group. There were no significant differences in age, sex, and tumor location. Of interest, temporal localization was not disproportionally involved.
Counterintuitively, we found that the tumors of small size with little edema became symptomatic with seizures rather than the larger tumors with massive edema. Hence, the tumor biology and interaction between tumor tissue and adjacent neurons might be of relevance in these tumors. One hypothetical assumption could be that seizure-favoring factors are more concentrated in little edema than in massive edema where they are more diluted.
A smaller tumor size as a predictive marker for seizures in glioblastoma was also described by Lee et al. 11 Small edema, on the other hand, has so far not been reported as a predictive marker and could be explained by the small tumor itself. Small tumor volume is known to be a favorable prognostic marker for survival in glioblastoma. 12 This does not apply to our seizure group, which consisted of significantly smaller tumors but showed a similar overall survival compared to the control group. The often reported survival benefit in glioblastoma with seizures is not yet fully understood. 13 A missing stratification in IDH-1 wildtype/mutation might be an explanation. Instead those tumors showed significantly higher levels of BCAT1. In addition, BCAT1 is associated with the aggressiveness of different types of cancer, especially glioma. So far, a relevant role for BCAT1 has been described in only IDH-1 wild-type cancers, which is not different from our results. 4, 14 But a different concentration of BCAT1 in IDH-1 wild-type glioblastoma has not been described so far and could be an explanation for the missing survival benefit in the seizure group, which consisted of significantly smaller tumors. BCAT1 is a known driver of malignancy in cancer and producer of glutamate. Its importance for survival was recently published in the context of acute myeloid leukemia. 15 However, to our knowledge there are no reports on different expression levels of BCAT1 in glioblastoma, which could explain the differences in survival. The oversupply of glutamate might then result in seizures as byproduct. BCAT1 is also one of the main producers of intracellular glutamate and thereby leads to an oversupply of glutamate, which in combination with the up-regulation of SLC7A11 can lead to seizures. 16 The small tumor size seems somewhat controversial to up-regulated BCAT1, since one would expect larger tumors. This might be due to a very early detection caused by their clinical presentation, namely seizures. BCAT1 and tumor size are both known to have a contrary influence on survival. In our study, these 2 factors presumably eliminated each other, as seen in our survival curve.
Both glutamine and glutamate carrier systems, SLC38A3 and SLC7A11, respectively, which were elevated in glioblastoma patients with seizures in our series, are responsible for different directions of glutamate flux. SLC38A3 mainly regulates the supply of glutamine for the synthesis of glutamate. SLC7A11 is responsible for glutamate release in the extracellular space. The overexpression of both leads to the abovementioned imbalance in glutamate homeostasis, which again can cause seizures. Altered expression of glutamate carrier systems and glutamate metabolizers like glutamine synthetase is also known in other acute brain pathologies. 17 Especially glutamine synthetase seems to play a role in TAS and might therefore interact with the glutamate carriers as described for temporal lobe epilepsies. 18, 19 SLC1A2 showed no significant difference between the 2 groups. Robert et al reported a correlation between the expression of SLC7A11 in glioblastoma and seizures and survival even though their data were not stratified for IDH-1 mutation status.
6
SLC38A3 specifically has so far not been connected to seizures in glioblastoma. The role of glutamate as a trigger for seizures in glioma in general due to alterations in glutamate carrier system (EAAT1/2) expression has been described elsewhere. 20 Although our study cannot provide a detailed follow-up for seizures due to the retrospective character of the clinical data, it may provide information on important aspects of TAS in IDH-1 wild-type glioblastomas.
Our results therefore might describe a subtype of glioblastoma, which as a result of disturbances in glutamate homeostasis present with seizures. To what extent up-regulation of BCAT1 is a predictor for a worse clinical course has to be confirmed in prospectively conducted trials.
In conclusion, our findings give a better understanding of the clinical course and the underlying mechanisms in patients with glioblastoma who present with seizures. There seems to be a correlation between glutamate oversupply and increased glutamate release, which than results in seizures. A small tumor volume with little edema represents a predictive marker for seizures in glioblastoma.
